1. P388 Analysis of the impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis programme. (25th January 2019) Authors: Farraye, F A; Qazi, T; Kotze, P G; Moore, G T; Kayhan, C; Mundayat, R; Maller, E; Su, C; Soonasra, A Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S301 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P479 Analysis of haematological changes in tofacitinib-treated patients with ulcerative colitis across Phase 3 induction and maintenance studies. (25th January 2019) Authors: Lichtenstein, G R; Moore, G T; Soonasra, A; Nduaka, C I; Kwok, K; Wang, L; Lawendy, N; Chan, G; Su, C; Loftus Jr., E V Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S351 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. THU0186 Magnitude and duration of early response with tofacitinib: post-hoc analysis of two phase 3, placebo-controlled studies. (15th June 2017) Authors: Aletaha, D; Kivitz, A; Valenzuela, G; Tesser, J; Hays, S; Li, H; Connell, CA; Bananis, E; Soonasra, A; Smolen, JS Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 272 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗